Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, which improve clinical outcomes in people with chronic kidney disease or systolic heart failure. Sodium-glucose cotransporter...

Full description

Saved in:

Bibliographic Details
Published in:	Circulation (New York, N.Y.) Vol. 145; no. 19; p. 1460
Main Authors:	Neuen, Brendon L, Oshima, Megumi, Agarwal, Rajiv, Arnott, Clare, Cherney, David Z, Edwards, Robert, Langkilde, Anna Maria, Mahaffey, Kenneth W, McGuire, Darren K, Neal, Bruce, Perkovic, Vlado, Pong, Annpey, Sabatine, Marc S, Raz, Itamar, Toyama, Tadashi, Wanner, Christoph, Wheeler, David C, Wiviott, Stephen D, Zinman, Bernard, Heerspink, Hiddo J L
Format:	Journal Article
Language:	English
Published:	United States 10.05.2022
Subjects:	Antihypertensive Agents - therapeutic use Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Female Glucose Humans Hyperkalemia - chemically induced Hyperkalemia - epidemiology Hypokalemia - chemically induced Hypokalemia - epidemiology Male Mineralocorticoid Receptor Antagonists - adverse effects Potassium Randomized Controlled Trials as Topic Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - epidemiology Sodium Sodium-Glucose Transporter 2 Inhibitors - adverse effects heart failure sodium-glucose transporter 2 inhibitors potassium type 2 renal insufficiency hyperkalemia diabetes mellitus chronic
ISSN:	1524-4539, 1524-4539
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!